132 related articles for article (PubMed ID: 15691114)
1. Fluorodeoxyglucose positron emission tomography scanning: basic principles and imaging of adult soft-tissue sarcomas.
Conrad EU; Morgan HD; Vernon C; Schuetze SM; Eary JF
J Bone Joint Surg Am; 2004; 86-A Suppl 2():98-104. PubMed ID: 15691114
[No Abstract] [Full Text] [Related]
2. Positron emission tomography of soft tissue sarcomas.
Israel-Mardirosian N; Adler LP
Curr Opin Oncol; 2003 Jul; 15(4):327-30. PubMed ID: 12874512
[TBL] [Abstract][Full Text] [Related]
3. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
4. PET imaging in soft tissue sarcomas.
Miraldi F; Adler LP; Faulhaber P
Cancer Treat Res; 1997; 91():51-64. PubMed ID: 9286488
[No Abstract] [Full Text] [Related]
5. Contemporary imaging in sarcoma.
Landa J; Schwartz LH
Oncologist; 2009 Oct; 14(10):1021-38. PubMed ID: 19789392
[TBL] [Abstract][Full Text] [Related]
6. A PET study of 18FDG uptake in soft tissue masses.
Lodge MA; Lucas JD; Marsden PK; Cronin BF; O'Doherty MJ; Smith MA
Eur J Nucl Med; 1999 Jan; 26(1):22-30. PubMed ID: 9933658
[TBL] [Abstract][Full Text] [Related]
7. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in sarcomas].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S96-102. PubMed ID: 12739341
[No Abstract] [Full Text] [Related]
8. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
Bredella MA; Caputo GR; Steinbach LS
AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
[TBL] [Abstract][Full Text] [Related]
9. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
[TBL] [Abstract][Full Text] [Related]
10. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma.
van Ginkel RJ; Hoekstra HJ; Pruim J; Nieweg OE; Molenaar WM; Paans AM; Willemsen AT; Vaalburg W; Koops HS
J Nucl Med; 1996 Jun; 37(6):984-90. PubMed ID: 8683328
[TBL] [Abstract][Full Text] [Related]
12. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
[TBL] [Abstract][Full Text] [Related]
13. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography.
Lucas JD; O'Doherty MJ; Cronin BF; Marsden PK; Lodge MA; McKee PH; Smith MA
Br J Surg; 1999 Apr; 86(4):550-6. PubMed ID: 10215835
[TBL] [Abstract][Full Text] [Related]
15. The Role of Imaging in Soft Tissue Sarcoma Diagnosis and Management.
Sharon CE; Straker RJ; Karakousis GC
Surg Clin North Am; 2022 Aug; 102(4):539-550. PubMed ID: 35952686
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
[TBL] [Abstract][Full Text] [Related]
17. [Biologic characterization of soft tissue sarcomes by positron emission tomography (initial results)].
Schwarzbach M; Willeke F; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Hinz U; Lehnert T; Herfarth C
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):635-9. PubMed ID: 14518332
[TBL] [Abstract][Full Text] [Related]
18. Intense accumulation of 18F-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors.
Park JH; Park EK; Kang CH; Kim CH; Choe JG; Noh W
Ann Nucl Med; 2009 Dec; 23(10):887-9. PubMed ID: 19862481
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
20. Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity.
Jager PL; Plaat BE; de Vries EG; Molenaar WM; Vaalburg W; Piers DA; Hoekstra HJ
Clin Cancer Res; 2000 Jun; 6(6):2252-9. PubMed ID: 10873075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
